Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orthocell Ltd ( (AU:OCC) ) just unveiled an update.
Orthocell Ltd has announced its financial results for the year ended 30 June 2025, reporting a significant increase in revenues from product sales by 74.2%, contributing to a total revenue growth of 36.4% from continuing operations. Despite the revenue growth, the company reported a net loss of $8.57 million, up 19.3% from the previous year, indicating ongoing challenges in achieving profitability. The announcement highlights Orthocell’s progress in revenue generation while also underscoring the financial hurdles it faces, which could impact its strategic positioning and stakeholder confidence.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a company based in Perth, Australia, operating in the biotechnology industry. It focuses on developing and commercializing regenerative medicine products, particularly for soft tissue injuries and musculoskeletal conditions.
Average Trading Volume: 617,569
Technical Sentiment Signal: Buy
Current Market Cap: A$293.8M
For an in-depth examination of OCC stock, go to TipRanks’ Overview page.